vTv Therapeutics, Inc. - Rasio total nilai perusahaan marang pendapatan VTVT

vTv Therapeutics Inc. (VTVT) develops small molecules for the treatment of type 1 diabetes, leveraging FDA priority status. Patents for these small-molecule agents create a significant barrier to entry for new players. A business valuation via EV/Sales captures the company's real value excluding debt, and this metric currently stands at -338.76. High costs associated with Phase 3 trials further restrict access to this niche.
Rincian metrik keuangan lan pasar vTv Therapeutics Inc (VTVT)

For vTv Therapeutics Inc. (VTVT), whose model is based on clinical trials without proprietary manufacturing plants and strict compliance with environmental regulations, this metric determines the market value of the business minus net debt relative to sales volume. By analyzing the current enterprise value-to-revenue ratio, an investor can assess the premium paid for intellectual capital and the sustainability of the company's valuation in the absence of a large-scale production cycle.